171 results on '"Shimizu, Yasushi"'
Search Results
2. Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms
3. Correction: Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma
4. Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis
5. Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma
6. Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
7. Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
8. Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
9. Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners
10. EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
11. Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis
12. Detailed analysis of failure patterns using deformable image registration in hypopharyngeal cancer patients treated with sequential boost intensity‐modulated radiotherapy
13. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy
14. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
15. Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment
16. Abstract 5210: Tumor immune characterization identifies age-stratified biomarkers for nivolumab in patients with head and neck squamous cell carcinoma: A nationwide collaborative study in Japan
17. Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.
18. Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method
19. Expression of Karyopherin Alpha 2 and Karyopherin Beta 1 Correlate with Poor Prognosis in Gastric Cancer
20. Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study
21. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial).
22. Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study
23. Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting
24. Developing WikiBOK: A Wiki-Based BOK Formulation-Aid System
25. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study
26. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer
27. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck
28. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)
29. Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck ( CheckMate 141)
30. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
31. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
32. Mean first passage times reconstruct the slowest relaxations in potential energy landscapes of nanoclusters
33. Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma
34. Abstract 953: JARID1 family inhibitor reduces generation of drug-resistant EGFR mutation-positive lung cancer cells
35. Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma
36. Abstract 953: JARID1 family inhibitor reduces generation of drug-resistant EGFR mutation-positive lung cancer cells
37. Faster and Profitable Production Optimization Decisions through Workflow Automation and Business Process Management - A Unique Concept
38. Changes of graph structure of transition probability matrices indicate the slowest kinetic relaxations
39. Late Onset of Non-islet Cell Tumor Hypoglycemia Managed via Multidisciplinary Treatment in a Patient with a Solitary Fibrous Tumor
40. Early prediction of lenvatinib treatment efficacy by using18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study
41. Abstract 1393: JARID1 family inhibitor recovers sensitivity of drug-tolerant subpopulation in lung cancer cell lines
42. Slowest kinetic modes revealed by metabasin renormalization
43. PERSONAL CONSTRUCT SYSTEM OF “COMMUNICATION EFFORT” AND EVALUATION FRAMEWORK OF ITS ACOUSTIC ENVIRONMENT
44. Evaluation of ambient noise including conversation in medical facilities
45. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
46. Abstract 2625: Clinicopathological features of programmed cell death ligand 1 (PD-L1) expression in resected non-small cell lung cancers
47. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity
48. Abstract 740: Silica promotes anchorage-independent growth of human bronchial cells via activation of NF-êB1 p50
49. Combined inhibition of EZH 2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells
50. Size dependence of vacancy migration energy in ionic nano particles: A potential energy landscape perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.